Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint

Date : 06/20/2019 @ 11:37PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 38.46  0.03 (0.08%) @ 3:22PM

Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint

Exelixis (NASDAQ:EXEL)
Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more Exelixis Charts.
   By Josh Beckerman 

Exelixis Inc. (EXEL) said a Phase 3 drug trial evaluating the combination of cobimetinib and atezolizumab to treat melanoma didn't meet its primary endpoint of progression-free survival.

Exelixis discovered cobimetinib, which was approved in the U.S. in 2015 and is co-promoted by Roche Holding AG's (ROG.EB) Genentech unit. Atezolizumab was developed by Genentech.

The safety profile observed in the IMspire170 trial was consistent with the known safety profiles of the individual drugs, Exelixis said.

Genentech, the sponsor of the trial, plans to present results at an upcoming medical meeting.

Exelixis shares fell 6.5% to $19.77 after hours.


Write to Josh Beckerman at josh.beckerman@wsj.com


(END) Dow Jones Newswires

June 20, 2019 19:22 ET (23:22 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.